Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 31st total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is presently 2.6 days.
Adaptimmune Therapeutics Stock Performance
NASDAQ ADAP traded up $0.01 during trading on Wednesday, reaching $0.59. The company's stock had a trading volume of 410,478 shares, compared to its average volume of 1,141,912. Adaptimmune Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.05. The firm has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.85. The firm has a market capitalization of $150.18 million, a price-to-earnings ratio of -2.67 and a beta of 2.42. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on ADAP shares. Guggenheim lowered their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday, November 15th. StockNews.com downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research note on Wednesday, November 27th. Finally, HC Wainwright decreased their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $2.79.
Read Our Latest Stock Report on Adaptimmune Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. Baillie Gifford & Co. boosted its stake in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company's stock valued at $15,944,000 after purchasing an additional 1,626,657 shares in the last quarter. FMR LLC increased its holdings in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock worth $1,655,000 after buying an additional 50,419 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after acquiring an additional 98,581 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 21,769 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. Institutional investors and hedge funds own 31.37% of the company's stock.
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Stories
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.